Cite this answer
DSIP: quick citable summary
DSIP is listed by PeptaHub as a sleep peptide with a reclassification pending legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “DSIP: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/dsip. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/dsip.
What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide isolated from rabbits in 1977, where intraventricular infusion enhanced delta-wave EEG. Human evidence is thin and mixed: the one controlled polysomnographic study in insomniacs found no significant change and no increase in slow-wave sleep.
Overview
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first isolated from rabbit brain in 1977. It is named for its ability to induce delta-wave (deep) sleep in rabbits given intraventricular infusions. That name has aged poorly: the one controlled polysomnographic study in human insomniacs found slow-wave sleep was not increased. Beyond sleep, small uncontrolled studies have looked at pain modulation and stress tolerance. It is used in the biohacking community for sleep and recovery, well ahead of the evidence.
Mechanism of action
DSIP modulates multiple neurotransmitter systems including GABAergic, glutamatergic, and serotonergic pathways. It promotes the release of luteinizing hormone (LH) while limiting somatostatin secretion, and modulates corticotropin activity, contributing to stress reduction. The proposed mechanism is sleep promotion without the sedation or dependency risks of benzodiazepines or Z-drugs, but the slow-wave sleep enhancement seen in rabbits has not been reproduced in the controlled human polysomnography data.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| sleep improvement | subcutaneous | 100–300 mcg | daily before bed | Inject 30-60 minutes before desired sleep time. Cycles of 2-4 weeks. Some users report best results with intermittent use. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert DSIP research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The DSIP dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
Schoenenberger & Monnier (PNAS 1977) isolated the nonapeptide from rabbits and showed that, of nine synthetic peptides infused intraventricularly in 58 rabbits under double-blind conditions, only DSIP itself enhanced delta and spindle EEG patterns. Human results are weaker and partly negative. Schneider-Helmert & Schoenenberger (Experientia 1981) gave intravenous DSIP to 6 middle-aged chronic insomniacs and reported longer sleep duration, fewer interruptions and slightly more REM sleep, with no daytime sedation. But Monti et al. (Int J Clin Pharmacol Res 1987), using polysomnography in a double-blind crossover design over four nights, found that although waking time and NREM sleep latency fell numerically, none of the changes reached significance against baseline or placebo nights, and slow-wave sleep specifically was not modified. Those authors concluded the sleep improvement was of little clinical significance. Larbig et al. (Eur Neurol 1984) reported significantly lower pain levels in 6 of 7 chronic pain patients in an uncontrolled pilot. Kovalzon & Strekalova (J Neurochem 2006) reviewed the field and called DSIP a still unresolved riddle. There are no large controlled trials.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with DSIP for synergistic effects.
Legal status
DSIP cannot legally be compounded in the US today. It is one of 12 peptides the FDA removed from Category 2 of the interim 503A bulk drug substances list on April 15, 2026, effective within seven calendar days, because the original nominators withdrew their nominations. Removal from Category 2 is not the same as being added to the Section 503A Bulks List or placed in Category 1, and the FDA has been explicit that it does not by itself make a substance eligible for compounding — enforcement discretion extends only to Category 1, and these substances were never in Category 1. The Pharmacy Compounding Advisory Committee took up DSIP, which the FDA lists under the name emideltide, on July 24, 2026 (docket FDA-2025-N-6895); FDA staff briefing documents recommended against adding it to the Bulks List. PCAC is advisory and formal rulemaking afterward typically takes 12 to 24 months. DSIP is not FDA-approved for any indication, is otherwise sold as a research peptide, and is not scheduled. Verify current federal and state rules before relying on access claims.
Sourcing & access
Reclassification in progress
DSIPis one of 12 peptides the FDA removed from its Category 2 “do not compound” list on April 15, 2026, after the original nominations were withdrawn. That removal did not place it on the 503A Bulks List or into Category 1, so it is not currently eligible for compounding. The Pharmacy Compounding Advisory Committee is reviewing these substances for the Bulks List; adding one requires formal rulemaking, which typically takes 12 to 24 months. See our regulatory status tracker and regulatory timeline for the current position.
Frequently asked questions
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first isolated from rabbit brain in 1977 by researchers studying thalamic delta-wave sleep induction. It is a nonapeptide (nine amino acids) that modulates sleep architecture and is found endogenously in the hypothalamus, limbic system, pituitary, and peripheral tissues. Its concentrations show circadian variation correlated with sleep-wake cycles.
DSIP is thought to modulate sleep through GABAergic, glutamatergic and serotonergic pathways rather than acting as a direct sedative, which is why it is described as mechanistically distinct from benzodiazepines and z-drugs. The honest answer on whether it improves sleep is that the evidence does not settle it. A 6-patient 1981 study reported longer, less interrupted sleep, while a double-blind crossover polysomnography study in 1987 found no significant change against placebo and no increase in slow-wave sleep at all.
Typical research protocols use 100 to 300 micrograms administered subcutaneously 30 to 60 minutes before the intended sleep period. Cycle lengths of 2 to 4 weeks are commonly used in practice. All dosing information is derived from limited human trials and self-experimentation reports, not from large-scale clinical studies. No FDA-approved reported study range exists.
No addiction, dependence, or withdrawal has been reported in the published literature on DSIP. That literature is small and contains no study designed to detect dependence liability, so this is an absence of reports rather than a demonstration of safety. It is a genuine mechanistic difference from benzodiazepines and z-drugs, which act directly at GABA-A receptors and carry established dependence risk, but that difference is a reason to expect lower risk, not evidence of it.
The most commonly reported side effects are morning grogginess, headache, and injection site reactions at the administration site. Some users report unusually vivid or intense dreams. Serious adverse events have not been documented in the available literature, though the evidence base consists primarily of small trials and anecdotal reports rather than large safety studies.
Research references
- Characterization of a delta-electroencephalogram (-sleep)-inducing peptidePubMed
- The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleepPubMed
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacsPubMed
- Delta sleep-inducing peptide (DSIP): a still unresolved riddlePubMed
- Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot studyPubMed